Beacon Therapeutics
PrivateLast Round
Series C
Jan 8, 2026
Est. Valuation
$618.75M
Total Funding Raised
$365M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Beacon Therapeutics is a biotechnology company that develops adeno-associated virus gene therapies to treat patients with rare and prevalent retinal diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Beacon Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Beacon Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 8, 2026 | ||||
| Series B | Jul 3, 2024 | ||||
| Series A | Jun 12, 2023 |
Key People
Founding team and executive leadership
Beacon Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series B |
| TCG Crossover | Series B |
| Forbion | Series C, Series B |
| Syncona | Series B, Series C, Series A |
| Oxford Science Enterprises | Series A, Series B, Series C |
| Life Sciences at Goldman Sachs Alternatives | Series C |
| Advent Life Sciences | Series B, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 8, 2026
$75M round raised at $618.75M post-money valuation.
- Jan 8, 2026
Colin Walsh, Managing Director at Goldman Sachs Alternatives, joins the board.
Beacon Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Beacon Therapeutics's valuation, stock price, and market status.